Soleno Therapeutics Inc  (SLNO)
Other Ticker:  
Price: $37.5000 $0.35 0.942%
Day's High: $37.904 Week Perf: -2.65 %
Day's Low: $ 36.61 30 Day Perf: -12.95 %
Volume (M): 191 52 Wk High: $ 93.00
Volume (M$): $ 7,166 52 Wk Avg: $51.10
Open: $36.86 52 Wk Low: $17.32

 Market Capitalization (Millions $) 429
 Shares Outstanding (Millions) 11
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -33
 Cash Flow (TTM) (Millions $) 33
 Capital Exp. (TTM) (Millions $) 0

Soleno Therapeutics Inc
Soleno Therapeutics Inc. is a biopharmaceutical company based in Redwood City, California. The company specializes in the development and commercialization of therapeutic products for rare diseases. Soleno's main focus is on the treatment of rare genetic disorders known as Prader-Willi Syndrome (PWS) and Angelman Syndrome (AS).

PWS is a genetic disorder that affects appetite, growth, cognitive function, and behavior. Soleno's lead product candidate, Diazoxide Choline Controlled-Release (DCCR), is being developed as a potential treatment for abnormal hyperphagia (excessive hunger) and obesity associated with PWS. The company has conducted clinical trials to evaluate the safety and efficacy of DCCR, with promising results that indicate a potential therapeutic benefit for PWS patients.

In addition to PWS, Soleno Therapeutics is also developing therapy options for AS, a neurogenetic disorder characterized by severe developmental delays, movement disorders, and sleep disturbances. The company is exploring potential treatments to address the underlying genetic causes of AS and improve the quality of life for affected individuals.

Soleno Therapeutics has a dedicated team of scientists, researchers, and professionals committed to advancing novel therapies for rare diseases. The company aims to fill the unmet medical needs of patients and bring innovative treatments to the market.

   Company Address: 203 Redwood Shores Parkway Redwood City 94065 CA
   Company Phone Number: 213-8444   Stock Exchange / Ticker: NASDAQ SLNO


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Stock Market Announcement

Soleno Therapeutics' Inducement Grants: Fostering Rare Disease Treatment Breakthroughs and Stock Growth

Published Fri, Apr 19 2024 8:07 PM UTC

Soleno Therapeutics Inc (NASDAQ: SLNO), a pioneering clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases, recently made a significant announcement regarding inducement grants made to six newly hired employees. These grants have been issued in line with Nasdaq Stock Market rules and regulations and are expected to...

Financing Agreement

Soleno Therapeutics Grant Inducement Awards to New Employees, Despite Leverage Ratio Challenges

Published Fri, Mar 8 2024 9:05 PM UTC

REDWOOD CITY, Calif., March 08, 2024 - Soleno Therapeutics, a renowned clinical-stage biopharmaceutical company specializing in developing innovative therapies for rare diseases, has recently made an important disclosure, as required by Nasdaq Stock Market rules: the granting of inducement awards to five new employees. This announcement affirms Soleno's commitment ...

Management Changes

Soleno Therapeutics Strengthens its Leadership Team to Drive Commercial Success and Global Expansion

Published Wed, Jan 24 2024 1:00 PM UTC

Soleno Therapeutics, a clinical-stage biopharmaceutical company specializing in developing innovative therapeutics for rare diseases, has recently made significant appointments to its leadership team. These strategic additions, along with the engagement of esteemed advisors, reflect the company's commitment to enhancing its commercial operations, expanding into Eur...


Soleno Therapeutics Empowers Shareholders with Inducement Awards, Bolstering Future Growth in Rare Disease Therapeutics.

Published Fri, Jan 5 2024 1:00 PM UTC

Soleno Therapeutics Empowers Shareholders with Inducement Awards
REDWOOD CITY, Calif., Jan. 05, 2024 - Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, has recently announced the grant of inducement awards to three new employees. This announcement comes as per th...

Soleno Therapeutics Inc

Soleno Therapeutics Inc Reports Surge in Operating Shortfall for Q3 2023

Over the past five days, the shares of Soleno Therapeutics Inc, a clinical-stage biopharmaceutical company developing therapeutics for rare diseases, have shown a slight improvement of 0.13%. However, this brings the year-to-date performance to a decrease of 29.44%. Currently trading on the NASDAQ, the shares are 50.1% below their 52-week average.
As the reporting cycle for July to September 2023 resumes, several corporations, including those in the Medical Equipment & Supplies sector, have reported their respective earnings. Soleno Therapeutics Inc, in particular, recently disclosed an operating shortfall of $-10.382 million for the three months ending September 30, 2023. This figure represents a significant increase compared to the $-6.235 million operating shortfall in the same quarter of the previous year.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com